Metabolic implication of tigecycline as an efficacous second-line treatment for sorafenib-resistant hepatocellular carcinoma
Published: 16 July 2020| Version 1 | DOI: 10.17632/t5z8v7752m.1
Contributor:
Martina MeßnerDescription
Meßner M., et al.
Files
Institutions
Paracelsus Medizinische Privatuniversitat, Ludwig-Maximilians-Universitat Munchen
Categories
Antibiotics, Drug Resistance, Hepatocellular Carcinoma, Relapse Prevention